Paul Shami
Director of Acute Leukemia and Myeloid Diseases · Univ of Utah Sch of Med
Credentials: · · · ·
History
Research
Evidence of increased angiogenesis in patients with acute myeloid leukemia
Blood · 2000 · Last of 3 authors · 422 citations
Blood · 1995 · 382 citations
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2019 · 359 citations
21 papers
14 papers
- MT
14 papers
- LM
13 papers
12 papers
12 papers
11 papers
- BS
10 papers
Grants
- 2010–2016
Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
National Cancer Institute · R44
PI · $1.2M · Jsk Therapeutics, Inc.
- 2008–2013
Development of JS-K as an Anti-Leukemic Agent
National Cancer Institute · R01
Contact PI · $2.6M · Utah State Higher Education System--University of Utah
- 2002–2006
Genetic Targets of Nitric Oxide in Leukemia Cells
National Cancer Institute · R01
Contact PI · $623.4K · Utah State Higher Education System--University of Utah
- 2005–2006
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $419 · Utah State Higher Education System--University of Utah
Clinical trials
- 2026–2027
Principal investigator · Not yet recruiting
University of Utah
- 2024–2027
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
- 2013–2015
Principal investigator · Completed · Early phase 1
Jazz Pharmaceuticals
- 2011–2014
Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients
Principal investigator · Completed · Phase 1
University of Utah